Published in Bioorg Med Chem Lett on January 17, 2005
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature (2010) 5.01
A two-stage differential hydrogen deuterium exchange method for the rapid characterization of protein/ligand interactions. J Biomol Tech (2007) 1.65
Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism. Structure (2012) 1.21
Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects. PPAR Res (2007) 1.18
Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol (2012) 1.16
An alternate binding site for PPARγ ligands. Nat Commun (2014) 1.06
PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) (2009) 1.03
A combined ligand- and structure-based virtual screening protocol identifies submicromolar PPARγ partial agonists. ChemMedChem (2011) 0.94
N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo. J Biol Chem (2011) 0.94
GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain. J Biol Chem (2012) 0.90
Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity. J Comput Aided Mol Des (2011) 0.86
Revisiting PPARγ as a target for the treatment of metabolic disorders. BMB Rep (2014) 0.85
Regulation of renin expression by the orphan nuclear receptors Nr2f2 and Nr2f6. Am J Physiol Renal Physiol (2012) 0.84
Structural mechanism for signal transduction in RXR nuclear receptor heterodimers. Nat Commun (2015) 0.83
Peroxisome proliferator-activated receptor gamma-dependent activity of indole ring-substituted 1,1-bis(3'-indolyl)-1-(p-biphenyl)methanes in cancer cells. Cancer Chemother Pharmacol (2009) 0.80
Therapeutic implications of targeting energy metabolism in breast cancer. PPAR Res (2013) 0.80
Targeting adipose tissue. Diabetol Metab Syndr (2012) 0.79
Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARγ Antagonists. ACS Med Chem Lett (2015) 0.77
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes. PLoS One (2014) 0.75
Trophic downgrading of planet Earth. Science (2011) 14.39
Status and ecological effects of the world's largest carnivores. Science (2014) 8.98
The mechanisms of action of PPARs. Annu Rev Med (2002) 6.71
Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature (2006) 5.81
Fibroblast growth factor 21 corrects obesity in mice. Endocrinology (2008) 5.66
Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes (2002) 3.21
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab (2013) 3.09
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology (2002) 2.72
Pleistocene rewilding: an optimistic agenda for twenty-first century conservation. Am Nat (2006) 2.69
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes (2006) 2.63
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A (2003) 2.35
Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol (2003) 1.96
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res (2007) 1.82
Indirect effects and traditional trophic cascades: a test involving wolves, coyotes, and pronghorn. Ecology (2008) 1.73
Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A (2003) 1.65
Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. J Biol Chem (2008) 1.60
AGPAT6 is a novel microsomal glycerol-3-phosphate acyltransferase. J Biol Chem (2008) 1.50
Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology (2002) 1.38
Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev (2011) 1.30
The ecological future of the North American bison: conceiving long-term, large-scale conservation of wildlife. Conserv Biol (2008) 1.27
Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate ester) iodo-resiniferatoxin. J Pharmacol Exp Ther (2002) 1.16
A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes (2004) 1.16
Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes (2002) 1.16
Localization of PPARdelta in murine central nervous system: expression in oligodendrocytes and neurons. Brain Res (2003) 1.15
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One (2013) 1.15
A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem (2002) 1.13
A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11. Gene (2003) 1.09
A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core. Bioorg Med Chem Lett (2005) 0.98
Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome. Endocrine (2006) 0.95
Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists. Bioorg Med Chem Lett (2009) 0.95
Small-molecule insulin mimetic reduces hyperglycemia and obesity in a nongenetic mouse model of type 2 diabetes. Endocrinology (2004) 0.91
Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo. Eur J Pharmacol (2009) 0.90
Differential potencies of naturally occurring regioisomers of nitrolinoleic acid in PPARgamma activation. Biochemistry (2009) 0.89
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists. Bioorg Med Chem Lett (2006) 0.89
Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree of unsaturation. J Med Chem (2009) 0.88
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity. J Med Chem (2005) 0.87
A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology (2003) 0.86
Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism. Endocrinology (2006) 0.86
Regulation of insulin signal transduction pathway by a small-molecule insulin receptor activator. Biochem J (2002) 0.86
A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology (2002) 0.86
Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoprotein. Cell Biol Int (2006) 0.85
Selective PPARgamma modulators with improved pharmacological profiles. Bioorg Med Chem Lett (2005) 0.85
A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. Eur J Pharmacol (2003) 0.85
Fluorinated piperidine acetic acids as gamma-secretase modulators. Bioorg Med Chem Lett (2009) 0.84
(2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents. Bioorg Med Chem Lett (2005) 0.84
The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities. Mol Pharmacol (2007) 0.84
A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects. Eur J Pharmacol (2008) 0.84
Identifying impediments to long-distance mammal migrations. Conserv Biol (2014) 0.83
Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators. J Med Chem (2011) 0.82
Novel 3,4-dihydroquinolin-2(1H)-one inhibitors of human glycogen phosphorylase a. Bioorg Med Chem Lett (2003) 0.82
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity. J Med Chem (2005) 0.80
Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists. J Med Chem (2010) 0.80
Climate change intensification of herbivore impacts on tree recruitment. Proc Biol Sci (2011) 0.80
Design, synthesis, and structure-activity relationship of podocarpic acid amides as liver X receptor agonists for potential treatment of atherosclerosis. Bioorg Med Chem Lett (2005) 0.80
Effects of heavy metals on immunocompetence of white-footed mice (Peromyscus leucopus). J Wildl Dis (2004) 0.79
Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists. Bioorg Med Chem Lett (2003) 0.79
Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett (2003) 0.79
Design of potent and selective GPR119 agonists for type II diabetes. Bioorg Med Chem Lett (2010) 0.79
Thiophenyl oxime-derived phosphonates as nano-molar class C beta-lactamase inhibitors reducing MIC of imipenem against Pseudomonas aeruginosa and Acinetobacter baumannii. Bioorg Med Chem Lett (2011) 0.79
Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs. Bioorg Med Chem Lett (2005) 0.79
MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities. Biochem Biophys Res Commun (2004) 0.79
5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists. Bioorg Med Chem Lett (2003) 0.79
Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists. Mol Pharmacol (2012) 0.79
(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents. J Med Chem (2004) 0.79
Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides. Bioorg Med Chem Lett (2009) 0.79
A novel surgical approach to subcondylar fractures of mandible. J Craniofac Surg (2008) 0.79
Discovery and development of dimeric podocarpic acid leads as potent agonists of liver X receptor with HDL cholesterol raising activity in mice and hamsters. Bioorg Med Chem Lett (2005) 0.78
NK1 antagonists based on seven membered lactam scaffolds. Bioorg Med Chem Lett (2006) 0.77